NeuFluent, a neuroscience innovation enterprise studio, has launched a brand new “clever implants and robotics initiative”.
The transfer expands its work in next-generation surgical improvements and broadens its know-how portfolio that features brain-computer interface and pharmaceutical know-how.
NeuFluent companions with main innovators to speed up neurological applied sciences from idea to market, with a observe document that features greater than 110 commercialized merchandise, over 250 patents, 25 exits, and a complete return on funding of greater than $20 billion.
Spearheading the brand new initiative is Dr. Kevin Foley, extensively credited as one of many world’s prime neurosurgeons and the pioneering inventor behind minimally invasive spinal surgical procedure. He has spent a long time advancing the broader discipline via image-guided strategies, disc regeneration, and robotics.
His contributions have earned him the American Affiliation of Neurological Surgeons (AANS) Cushing Medal for Technical Excellence and Innovation in Neurosurgery and the World Federation of Neurosurgical Societies William Beecher Scoville Award.
He’s a professor of neurosurgery, orthopedic surgical procedure, and biomedical engineering on the College of Tennessee Well being Science Middle.
Ryan Douglas, chairman and co-CEO of NeuFluent, says: “Dr. Kevin Foley is among the uncommon innovators who has repeatedly turned medical ideas into world requirements of care.
“Whereas his footprint in spinal robotics is famous, his capacity to architect scalable, AI-based applied sciences is what makes him the right match to steer this space of NeuFluent and assist us construct the way forward for neurosurgical care.”
Dr. Foley says: “I’ve spent my profession advancing minimally invasive strategies and robotics for the backbone, however the subsequent frontier of medication depends on clever implants and good robotics that may actively study and reply.
“What’s compelling about NeuFluent is our capacity to mix medical perception, AI, and engineering to architect good, scalable methods that can assist speed up the subsequent era of neurotechnology, vastly impacting sufferers and outcomes.”
NeuFluent merges specialists and know-how to advance:
- Mind-computer interface (BCI): Pediatric neurosurgeon Dr. Samuel Browd leads the development of applied sciences that allow direct communication between the mind and exterior methods for neurological monitoring and remedy. The NeuFluent BCI group additionally consists of neurosurgeon Dr. Jeff Ojemann of Seattle Youngsters’s Hospital; Dr. Dan Donoho, neurosurgeon at The George Washington College; and Craig Mundie, former chief analysis and technique officer for Microsoft.
- Pharmaceutical know-how: Led by Dr. Russell Lonser, chair of neurological surgical procedure at Ohio State, NeuFluent is creating new approaches to treating neurological circumstances via AI-based drug improvement and focused supply methods.
- Clever implants and robotics: Now led by Dr. Kevin Foley, NeuFluent is mixing its next-generation neurotechnology methods with good implant applied sciences and robotic methods designed to rework neurological care.
The brand new neural financial system
NeuFluent brings collectively leaders with experience throughout neuroscience, engineering, regulatory technique, manufacturing, and commercialization to develop and scale new applied sciences.
Its mannequin is designed to speed up how improvements transfer from idea to real-world use. Its method is main the shift towards the brand new neural financial system, the place quicker, data-driven improvement replaces conventional hardware-first fashions and allows innovators to extra quickly construct and scale their gadgets.
